Paul R. Fonteyne is Director of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 16,438 shares of APLS, which is worth approximately $505,797. The most recent transaction as insider was on Jan 01, 2024, when has been sold 3,341 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 16.4K
0% 3M change
25.51% 12M change
Total Value Held $505,797

PAUL R. FONTEYNE Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 01 2024
BUY
Grant, award, or other acquisition
-
3,341 Added 16.89%
16,438 Common Stock
Jan 01 2023
BUY
Grant, award, or other acquisition
-
3,867 Added 22.8%
13,097 Common Stock
Jan 01 2022
BUY
Grant, award, or other acquisition
-
4,230 Added 31.43%
9,230 Common Stock

Also insider at

AMAG
AMAG PHARMACEUTICALS, INC.
CVET
COVETRUS, INC. Healthcare
AMLX
Amylyx Pharmaceuticals, Inc. Healthcare
GLS
GELESIS HOLDINGS, INC. Healthcare
PRF

Paul R. Fonteyne

Director
Portland, ME

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS